Breast Cancer Research and Treatment

, Volume 119, Issue 1, pp 137–144

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

  • Elisabeth R. Garwood
  • Anjali S. Kumar
  • Frederick L. Baehner
  • Dan H. Moore
  • Alfred Au
  • Nola Hylton
  • Chris I. Flowers
  • Judy Garber
  • Beth-Ann Lesnikoski
  • E. Shelley Hwang
  • Olofunmilao Olopade
  • Elisa Rush Port
  • Michael Campbell
  • Laura J. Esserman
Clinical trial

DOI: 10.1007/s10549-009-0507-x

Cite this article as:
Garwood, E.R., Kumar, A.S., Baehner, F.L. et al. Breast Cancer Res Treat (2010) 119: 137. doi:10.1007/s10549-009-0507-x

Abstract

The purpose of this study is to determine the biologic impact of short-term lipophilic statin exposure on in situ and invasive breast cancer through paired tissue, blood and imaging-based biomarkers. A perioperative window trial of fluvastatin was conducted in women with a diagnosis of DCIS or stage 1 breast cancer. Patients were randomized to high dose (80 mg/day) or low dose (20 mg/day) fluvastatin for 3–6 weeks before surgery. Tissue (diagnostic core biopsy/final surgical specimen), blood, and magnetic resonance images were obtained before/after treatment. The primary endpoint was Ki-67 (proliferation) reduction. Secondary endpoints were change in cleaved caspase-3 (CC3, apoptosis), MRI tumor volume, and serum C-reactive protein (CRP, inflammation). Planned subgroup analyses compared disease grade, statin dose, and estrogen-receptor status. Forty of 45 patients who enrolled completed the protocol; 29 had paired Ki-67 primary endpoint data. Proliferation of high grade tumors decreased by a median of 7.2% (P = 0.008), which was statistically greater than the 0.3% decrease for low grade tumors. Paired data for CC3 showed tumor apoptosis increased in 38%, remained stable in 41%, and decreased in 21% of subjects. More high grade tumors had an increase in apoptosis (60 vs. 13%; P = 0.015). Serum CRP did not change, but cholesterol levels were significantly lower post statin exposure (P < 0.001). Fluvastatin showed measurable biologic changes by reducing tumor proliferation and increasing apoptotic activity in high-grade, stage 0/1 breast cancer. Effects were only evident in high grade tumors. These results support further evaluation of statins as chemoprevention for ER-negative high grade breast cancers.

Keywords

Statin(s)Breast cancerDCIS ductal carcinoma in situHMG-CoA reductase inhibitorsCancer prevention

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Elisabeth R. Garwood
    • 1
    • 2
  • Anjali S. Kumar
    • 3
  • Frederick L. Baehner
    • 4
  • Dan H. Moore
    • 5
  • Alfred Au
    • 4
  • Nola Hylton
    • 6
  • Chris I. Flowers
    • 6
  • Judy Garber
    • 8
  • Beth-Ann Lesnikoski
    • 7
  • E. Shelley Hwang
    • 1
  • Olofunmilao Olopade
    • 9
  • Elisa Rush Port
    • 10
  • Michael Campbell
    • 1
  • Laura J. Esserman
    • 1
    • 11
  1. 1.Department of SurgeryUniversity of CaliforniaSan FranciscoUSA
  2. 2.Pennsylvania State University College of MedicineHersheyUSA
  3. 3.Department of SurgeryUniversity of California, East bayOaklandUSA
  4. 4.Department of PathologyUniversity of CaliforniaSan FranciscoUSA
  5. 5.Department of Epidemiology and BiostatisticsUniversity of CaliforniaSan FranciscoUSA
  6. 6.Department of Radiology and Biomedical ImagingUniversity of CaliforniaSan FranciscoUSA
  7. 7.Department of SurgeryBeth Israel Deaconness Medical CenterBostonUSA
  8. 8.Department of MedicineDana-Farber Cancer InstituteBostonUSA
  9. 9.Department of MedicineUniversity of ChicagoChicagoUSA
  10. 10.Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  11. 11.Carol F. Buck Breast Care CenterSan FranciscoUSA